| Recruitment status | Completed |
| Unique ID issued by UMIN | UMIN000020975 |
| Receipt No. | R000024205 |
| Official scientific title of the study | Clinical trial to evaluate the efficacy and safety of [11C]K-2 in healthy volunteers |
| Date of disclosure of the study information | 2016/02/12 |
| Last modified on | 2016/11/08 (Ver. 3) |
| Basic information | ||
| Official scientific title of the study | Clinical trial to evaluate the efficacy and safety of [11C]K-2 in healthy volunteers | |
| Title of the study (Brief title) | Clinical trial to evaluate the efficacy and safety of [11C]K-2 | |
| Region |
|
|
| Condition | ||
| Condition | healthy volunteer | |
| Classification by specialty |
|
|
| Classification by malignancy | Others | |
| Genomic information | NO | |
| Objectives | |
| Narrative objectives1 | The purpose of this trial is to evaluate the efficacy and safety of [11C]K-2, recognizing AMPA receptors, in healthy volunteers. |
| Basic objectives2 | Safety,Efficacy |
| Basic objectives -Others | |
| Trial characteristics_1 | |
| Trial characteristics_2 | |
| Developmental phase | |
| Assessment | |
| Primary outcomes | To measure the dinamics and distribution volumes of [11C]K-2 in the brain. |
| Key secondary outcomes | To study the adverse event about [11C]K-2 during post 4-10 days after administration of it. |
| Base | |
| Study type | Interventional |
| Study design | |
| Basic design | Single arm |
| Randomization | Non-randomized |
| Randomization unit | |
| Blinding | Open -no one is blinded |
| Control | Uncontrolled |
| Stratification | |
| Dynamic allocation | |
| Institution consideration | |
| Blocking | |
| Concealment | |
| Intervention | ||
| No. of arms | 1 | |
| Purpose of intervention | Prevention | |
| Type of intervention |
|
|
| Interventions/Control_1 | single administration of [11C]K-2 | |
| Interventions/Control_2 | ||
| Interventions/Control_3 | ||
| Interventions/Control_4 | ||
| Interventions/Control_5 | ||
| Interventions/Control_6 | ||
| Interventions/Control_7 | ||
| Interventions/Control_8 | ||
| Interventions/Control_9 | ||
| Interventions/Control_10 | ||
| Eligibility | ||||
| Age-lower limit |
|
|||
| Age-upper limit |
|
|||
| Gender | Male | |||
| Key inclusion criteria | 1. japanese healthy volunteer
2. male 3. age is between 20-40 4. BMI is between 18.5-25.0 5. The laboratory data in the Blood test is within normal limit 6. HBV, HCV, HIV, syphilis negative 7. The man who can agree by himself |
|||
| Key exclusion criteria | 1. The man cannot agree by himself
2. The man who has past or current history of psychiatric disorder 3. current smoker or past smoker who quit smoking within 6 months 4. The man who is disclosed brain disease by MRI study 5. The man who has pacemaker or metal object inside his body 6. The man who has tatoo 7. claustrophobia 8. The man who participates in clinical trial where he underwent nuclear medicine scan within 6 months 9. The man who donates his blood 400ml within 12 weeks or 200ml within 4 weeks or more little within 2 weeks 10. The man who participates in other clinical trial within 12 weeks 11. The man who continues and cannot quit using drugs 12. The man who is judged inadequate by the research medical doctor |
|||
| Target sample size | 8 | |||
| Research contact person | |
| Name of lead principal investigator | tomoyuki miyazaki |
| Organization | Yokohama city university, school of medicine |
| Division name | physiology |
| Address | Fukuura 3-9, Kanazawa-ku, Yokohama, Kanagawa |
| TEL | 045-787-2579 |
| johney@yokohama-cu.ac.jp | |
| Public contact | |
| Name of contact person | akane sano |
| Organization | Yokohama city university, school of medicine |
| Division name | physiology |
| Address | Fukuura 3-9, Kanazawa-ku, Yokohama, Kanagawa |
| TEL | 045-787-2579 |
| Homepage URL | |
| akane@med.yokohama-cu.ac.jp | |
| Sponsor | |
| Institute | Yokohama city university, school of medicine |
| Institute | |
| Department | |
| Funding Source | |
| Organization | Creation of innovation centers for advanced interdisciplinary research areas program |
| Organization | |
| Division | |
| Category of Funding Organization | Japanese Governmental office |
| Nationality of Funding Organization | |
| Other related organizations | |
| Co-sponsor | |
| Name of secondary funder(s) | |
| Secondary IDs | |
| Secondary IDs | NO |
| Study ID_1 | |
| Org. issuing International ID_1 | |
| Study ID_2 | |
| Org. issuing International ID_2 | |
| IND to MHLW | |
| Institutions | |
| Institutions | |
| Other administrative information | |||||||
| Date of disclosure of the study information |
|
||||||
| Progress | |||||||
| Recruitment status | Completed | ||||||
| Date of protocol fixation |
|
||||||
| Anticipated trial start date |
|
||||||
| Last follow-up date |
|
||||||
| Date of closure to data entry | |||||||
| Date trial data considered complete | |||||||
| Date analysis concluded |
|
||||||
| Related information | |
| URL releasing protocol | |
| Publication of results | Unpublished |
| URL releasing results | |
| Results | |
| Other related information | |
| Management information | |||||||
| Registered date |
|
||||||
| Last modified on |
|
||||||
| Link to view the page | |
| URL(English) | https://upload.umin.ac.jp/cgi-open-bin/icdr_e/ctr_view.cgi?recptno=R000024205 |